Everolimus Tablet shortage
To Be Discontinued 15 presentations · 4 manufacturers · first FDA posting 2025-11-03 · last update 2026-10-14
Manufacturers: Endo Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., a Viatris Company, Par Health, USA LLC, Teva Pharmaceuticals USA, Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Everolimus, Tablet, 2.5 mg (NDC 49884-119-91) | Endo Pharmaceuticals, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/06/2026 Updated 01/06/2026 Discontinued 01/06/2026 |
| Everolimus, Tablet, 5 mg (NDC 49884-125-91) | Endo Pharmaceuticals, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/06/2026 Updated 01/06/2026 Discontinued 01/06/2026 |
| Everolimus, Tablet, 7.5 mg (NDC 49884-127-91) | Endo Pharmaceuticals, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/06/2026 Updated 01/06/2026 Discontinued 01/06/2026 |
| Everolimus, Tablet, 10 mg (NDC 49884-128-91) | Endo Pharmaceuticals, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/06/2026 Updated 01/06/2026 Discontinued 01/06/2026 |
| Everolimus, Tablet, 2 mg (NDC 0378-0005-85) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 11/03/2025 Updated 11/03/2025 Discontinued 11/03/2025 |
| Everolimus, Tablet, 3 mg (NDC 0378-0006-85) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 11/03/2025 Updated 11/03/2025 Discontinued 11/03/2025 |
| Everolimus, Tablet, 5 mg (NDC 0378-0007-85) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 11/03/2025 Updated 11/03/2025 Discontinued 11/03/2025 |
| Everolimus, Tablet, .25 mg (NDC 49884-158-02) | Par Health, USA LLC | To Be Discontinued | — | A business decision was made to withdraw from sale. | Posted 10/14/2026 Updated 10/14/2026 Discontinued 10/14/2026 |
| Everolimus, Tablet, .5 mg (NDC 49884-159-02) | Par Health, USA LLC | To Be Discontinued | — | A business decision was made to withdraw from sale. | Posted 10/14/2026 Updated 10/14/2026 Discontinued 10/14/2026 |
| Everolimus, Tablet, .75 mg (NDC 49884-160-02) | Par Health, USA LLC | To Be Discontinued | — | A business decision was made to withdraw from sale. | Posted 10/14/2026 Updated 10/14/2026 Discontinued 10/14/2026 |
| Everolimus, Tablet, 1 mg (NDC 49884-283-02) | Par Health, USA LLC | To Be Discontinued | — | A business decision was made to withdraw from sale. | Posted 10/14/2026 Updated 10/14/2026 Discontinued 10/14/2026 |
| Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 03/02/2026 Updated 03/02/2026 Discontinued 03/02/2026 |
| Everolimus, Tablet, 5 mg (NDC 0093-7767-24) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 03/02/2026 Updated 03/02/2026 Discontinued 03/02/2026 |
| Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 03/02/2026 Updated 03/02/2026 Discontinued 03/02/2026 |
| Everolimus, Tablet, 10 mg (NDC 0093-7769-24) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 03/02/2026 Updated 03/02/2026 Discontinued 03/02/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)